Skilax

Quick links to important sections

Skilax

Selected form

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Skilax

Property Description
Active ingredient Sodium picosulfate
Form Oral drops (solution), Tablets
Pharmacological class Stimulant laxative, Pro-drug
Common use Symptomatic relief of occasional constipation
Origin Synthetic (Triarylmethane derivative)

What Type of Medicine is Skilax? (Identity and Classification)

Skilax is a synthetic medicinal preparation classified pharmacologically as a stimulant laxative, a specialized gastrointestinal agent. Its sole active ingredient is sodium picosulfate. This compound functions as a pro-drug, meaning the substance itself is chemically inert upon ingestion and requires activation in the body to become effective.

As a stimulant laxative, its pharmacological action is distinct from agents that simply add bulk or draw water into the colon. The active component is classified as a triarylmethane derivative, emphasizing its engineered nature and targeted function within the lower digestive tract. This pro-drug classification ensures the medicine is primarily activated at the site where its effects are needed.


Form and Composition of the Sodium Picosulfate Entity

The sodium picosulfate in Skilax is available for oral administration in multiple dosage forms, notably oral drops (an aqueous solution) and various tablet formulations. This variety in form offers flexibility for patients, particularly those who may have difficulty swallowing solid medications.

The active substance is metabolized by colonic bacteria to its active form, an action critical for its efficacy. This reliance on the bacterial flora for activation highlights its nature as a targeted single-ingredient product. The distinction in form provides flexibility but does not alter the drug's fundamental pro-drug status.


General Purpose and High-Level Action

The general therapeutic purpose of Skilax is to provide symptomatic relief for instances of occasional constipation. Its function is achieved through a local effect primarily within the large intestine.

This localized action, which promotes the reliable emptying of the large intestine, defines its high-level benefit to normalize short-term bowel function. By stimulating the muscle contractions (peristalsis) that move contents through the bowel, it effectively acts to accelerate colonic transit.

Regulatory References

  1. MHRA Public Assessment of Stimulant Laxatives

What side effects are possible with Skilax?

Possible Side Effects and Safety Information

The safety profile for Skilax (sodium picosulfate) is organized by regulatory authorities according to the frequency and type of adverse reaction observed in clinical use. These classifications focus primarily on effects within the Gastrointestinal system and potential disturbances in the body's fluid and chemical balance.


Frequency-Classified Adverse Reactions

The most frequently documented reactions are related to the gastrointestinal tract, consistent with the medicine's targeted action. Regulatory documents classify the following effects:

  • Very Common (occurring in 1 in 10 or more people): Diarrhoea.
  • Common (occurring in 1 in 100 to less than 1 in 10 people): Abdominal pain, abdominal cramps, abdominal discomfort, nausea, vomiting, and headache.
  • Uncommon (occurring in 1 in 1,000 to less than 1 in 100 people): Dizziness, hypersensitivity reactions, and hypokalaemia (low potassium).

Serious Safety Considerations

The most serious safety concerns officially documented relate to systemic balance. Excessive or prolonged use may lead to fluid and electrolyte abnormalities, including dehydration and critically low levels of substances like sodium (hyponatraemia) or potassium (hypokalaemia). These disturbances can potentially lead to rare but serious complications, such as seizures or cardiac arrhythmias. Furthermore, older adults and patients with renal impairment are cited in regulatory documents as populations requiring particular caution due to an increased risk of these fluid imbalances.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for sodium picosulfate based on the physiological consequences of excessive exposure. The primary risk is linked to acute, severe fluid loss resulting in systemic physiological instability.

Feature Official Regulatory Description
Documented Overdose Manifestations Symptoms include severe diarrhea and abdominal cramps. Resultant fluid loss can lead to dehydration, nausea, vomiting, and headache.
Physiological Systems Affected The Cardiovascular and Nervous Systems are affected by resulting fluid and electrolyte disturbances, potentially causing cardiac arrhythmias and seizures.
Dose-Related Factors Overdose risk is associated with the ingestion of significantly high doses or prolonged, chronic excessive use.
Population-Specific Overdose Notes Elderly patients and children are documented to be at increased risk for developing severe dehydration and subsequent electrolyte disturbances following overexposure.

Overdose Classifications

Classification Regulatory Status
Severity Classification Overdose can lead to life-threatening outcomes, particularly those associated with profound fluid and electrolyte imbalance.
Emergency-Response Statement Official instructions mandate that the patient or caregiver contact a poison control center or emergency room at once when overdose is suspected.

Resulting Overdose Structure

Official regulatory information states that the primary danger in overdose stems from severe gastrointestinal fluid loss, leading to a profound fluid and electrolyte imbalance. This imbalance is documented as the cause of serious, acute manifestations such as seizures, cardiac arrhythmias, and syncope (fainting). Management procedures described in official labels are symptomatic and supportive, emphasizing the immediate restoration of fluid and electrolyte balance to stabilize the patient.

Therapeutic Uses of Skilax

Quick Facts: Skilax Uses

  • Addresses: Occasional constipation.
  • Supports: Bowel movement regulation.
  • Assists: Bowel cleansing before specific medical procedures or surgery.

Skilax (sodium picosulfate) is a pharmaceutical compound utilized in the management of certain gastrointestinal conditions. Its primary therapeutic domains include providing relief for episodes of occasional constipation. The compound helps to encourage and maintain predictable bowel movements in appropriate patients.

In specialized clinical settings, the medication is also indicated as part of a regimen to support thorough bowel clearance. This preparation is necessary before certain diagnostic and investigative medical procedures, such as colonoscopy, or prior to specific surgical interventions. Medical professionals prescribe the product for these defined uses to facilitate optimal viewing conditions during examination or to reduce risks during surgery.

Patients should always follow the prescribing healthcare provider’s recommendations when using this compound, which is classified as a stimulant laxative.

Eligibility and Restrictions for Use

Skilax (sodium picosulfate) eligibility is defined by absolute contraindications and population-specific restrictions documented in regulatory labeling. The medicine is primarily approved for use in adults.

Eligibility scope Classification
Allowed Populations Adults and children aged 10 years and older (for constipation relief) or 9 years and older (for bowel cleansing, depending on formulation).
Use Not Recommended Children under 10 years of age for constipation relief. Use during pregnancy or continuous daily use exceeding five days without medical investigation.

Official Eligibility Statements:

  • The medicine is contraindicated in patients with a known hypersensitivity to the ingredients.
  • Absolute contraindications include acute abdominal conditions such as ileus, gastrointestinal obstruction or perforation, toxic colitis, toxic megacolon, and severe dehydration.
  • The drug is contraindicated for patients with severe renal impairment (Creatinine Clearance <30 mL/minute), particularly in combination products.
  • Caution is required for elderly patients and individuals with conditions that increase the risk of cardiac arrhythmias or seizures due to the potential for electrolyte disturbances.

Connection to the overall eligibility profile: Regulatory documents define eligibility primarily through absolute contraindications related to acute GI integrity and systemic fluid/electrolyte balance. The remaining rules focus on age-specific non-establishment of use and conditional warnings for vulnerable populations.

What should I know about interactions with other medicines?

The official interaction profile for Skilax (sodium picosulfate) is defined by its effects on gastrointestinal transit and fluid balance, according to regulatory documents.

Interaction Scope and Classification

The primary interactions are classified as pharmacokinetic (PK) and pharmacodynamic (PD). The PK interaction involves the risk of reduced absorption for many oral medicines due to accelerated bowel movement. The PD interaction involves an additive risk of fluid and electrolyte abnormalities when co-administered with certain drug classes. Other laxatives are officially prohibited for co-administration.

Official Interaction Statements

  • Specific agents, including Digoxin, Iron Supplements, Chlorpromazine, and certain Antibiotics (Tetracyclines, Fluoroquinolones), are documented to have decreased systemic exposure.
  • A timing separation rule is mandated: these specific medicines must be taken at least 2 hours before and not less than 6 hours after Skilax administration.
  • The risk of fluid and electrolyte issues is officially noted to increase with co-administration of Diuretics, ACE Inhibitors, ARBs, NSAIDs, and medications that lower the seizure threshold.
  • Concomitant use of Antibiotics may decrease the therapeutic effect of Skilax by disrupting the bacterial flora required for its activation.
  • Restrictions include avoiding Solid Food, Dairy, and Alcohol during the administration protocol.

This structure ensures that potential alterations to drug exposure and the additive risk of electrolyte imbalance are formally addressed as required by government health authorities.

Mechanism of Action

How Skilax Works

Pro-drug Activation by Colonic Microflora

The mechanism of Skilax (sodium picosulfate) is defined by a strictly localized action requiring an initial biotransformation. The compound functions as a pro-drug that is chemically transformed by bacterial sulfatases—enzymes produced by the colonic microflora in the large intestine. This hydrolytic cleavage generates the active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane ( BHPM), which is the primary determinant of the onset of action.

️ Dual Action: Stimulating Motility and Modulating Fluid

Once activated, BHPM performs two functions simultaneously on the colon wall. It acts as a contact irritant to directly stimulate enteric sensory neurons (in the myenteric plexus), dramatically enhancing propulsive muscle contractions (peristalsis). Concurrently, it engages colonic epithelial cells to inhibit net reabsorption of water and sodium , maintaining fluid volume in the bowel.

Resulting Physiological Consequence

The combined effect of increased propulsive motility and the elevated fluid content establishes the physiological conditions that enhance bowel evacuation. This mechanistic cascade results in an accelerated colonic transit time and a softer, bulkier stool mass, which collectively triggers the final stage of the defecation reflex.

Dosage and Administration Information

Official Administration Guidelines for Skilax (Sodium Picosulfate)

The correct use of Skilax, or its active ingredient sodium picosulfate, is strictly defined by two separate protocols based on the product’s purpose: short-term constipation relief or procedural bowel cleansing.


Dosing for Short-Term Constipation Relief

Property Official Instruction
Route of Administration Oral only (via liquid drops or tablets)
Standard Adult Dose Start with 5 mg, increasing up to a maximum of 10 mg once daily.
Timing Administer once daily, typically at bedtime, to produce an effect the following morning.
Duration Restriction Not to be used continuously for more than five days.
Age-Group Rule Generally indicated for pediatric patients 10 years and older under professional guidance.

Dosing for Bowel Cleansing (Procedural Use)

When used as part of a bowel preparation regimen (often in combination products), two separate doses are required, typically 10 mg of sodium picosulfate per dose.

  • Administration: The regimen is taken as two time-separated doses, following either a Split-Dose or Day-Before schedule.
  • Preparation: Powder formulations must be reconstituted with cold water immediately before ingestion; ready-to-drink solutions are taken directly.
  • Special Conditions: The patient must maintain a clear liquid diet throughout the preparation. Additional clear liquids are mandatory after each dose, and oral medications should not be taken within one hour of the start of each dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus and Initial Effects

Research has focused on the agent's hypothesized action. Studies have examined whether it influences joint function and pain symptoms. In animal models, research explored whether administration of the agent may influence the time to onset of perceived effects.


Clinical Trials in Rheumatoid Arthritis (RA)

Multiple randomized controlled trials (RCTs) have focused on exploring the agent's potential role in managing rheumatoid arthritis. The agent was evaluated in multiple studies across various populations and disease severities.

  • Symptom Changes: Studies examined perceived changes in the Disease Activity Score 28 (DAS28) and the Health Assessment Questionnaire (HAQ). Some studies reported observations related to the duration of changes in joint swelling.
  • Tolerability Profile: Tolerability profiles were documented in the trials.

Dosage and Administration Studies

Dose-ranging studies focused on determining regimens that maintained tolerability while exploring potential benefits.

  • Administration Timing: In some trials, dosing regimens involved administration in the evening to explore potential benefits on morning stiffness.
  • Combination Therapy: Studies compared outcomes between combination administration and monotherapy, primarily with standard disease-modifying antirheumatic drugs (DMARDs).

Research in Special Populations

  • Mild Liver Impairment: The tolerability of the regimen in participants with mild liver impairment was specifically evaluated in trials.
  • Inflammation Biomarkers: Research explored whether the agent affected biomarkers of inflammation, such as C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR), across all study groups.

Preclinical Data

Early research has also examined pain-related behaviors in rodent models.

Frequently Asked Questions (FAQ)

Common questions about Skilax (FAQ)

Q: What is the main approved medical use for Skilax?

A: Official regulatory documents state that Skilax is primarily indicated for cleansing the colon as a preparation for certain medical procedures, such as colonoscopy. Additionally, some specific product formulations containing this agent are approved for the short-term relief of constipation.


Q: How is Skilax different from other similar treatments?

A: The way Skilax works is defined by its unique mechanism as a pro-drug; it is chemically inactive until specialized bacteria in the gut break it down into the active compound. This active compound works to stimulate muscle movement in the colon. In some procedural uses, this agent is combined with an osmotic laxative to further enhance its effect.


Q: Is Skilax a controlled substance or scheduled medication?

A: No. Official drug classification information confirms that Skilax is not designated as a controlled substance or scheduled medication by U.S. regulatory authorities.


Q: How quickly can I expect Skilax to start working?

A: Since the drug must travel to the large intestine and be activated by gut bacteria, the time it takes to start working is generally between 12 and 24 hours after it is taken. This slower onset is why it is often recommended for use at bedtime when taken for constipation relief.


Q: What are the most commonly reported side effects of Skilax?

A: According to official regulatory documents, the most commonly reported adverse events include general discomforts such as nausea, headache, and various forms of abdominal pain or cramping.


Q: Are there any serious or rare side effects associated with Skilax?

A: Official labeling highlights that serious effects, while less common, may occur, particularly if the drug is misused or the patient is at risk. These can include severe dehydration, imbalances in necessary body salts (electrolyte abnormalities), and the potential for complications like seizures or kidney problems.


Q: Can Skilax affect my ability to drive or operate machinery?

A: Official warnings caution that Skilax may affect coordination, reaction time, or judgment. Warnings note that driving or operating machinery may need to be avoided until the medication's effects on the individual are known.


Q: Does Skilax interact with common over-the-counter pain relievers?

A: Regulatory warnings state that taking certain non-prescription pain relievers, specifically NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), concurrently can increase the risk of serious fluid loss and changes to electrolyte levels.


Q: Is it safe to take Skilax with herbal supplements or vitamins?

A: The accelerated movement of the gut caused by Skilax can affect how the body absorbs many oral medications, including supplements. Official documents specifically list interactions with certain minerals, such as Iron, and note the possibility of reduced systemic exposure to many orally administered medicines.


Q: Can taking Skilax affect the results of certain lab tests?

A: Since Skilax affects fluid balance, regulatory documents note a risk of fluid and electrolyte abnormalities (changes in the balance of essential salts in the body). Due to this risk, laboratory assessments may be required before and after its use, which confirms that it affects the components measured in blood work.


Q: Are there specific health conditions that would prevent me from using Skilax?

A: Yes, official regulatory labeling lists several conditions that prevent the use of Skilax (contraindications). These typically include conditions like severe dehydration, a physical obstruction or perforation in the gastrointestinal tract, and an active acute stage of inflammatory bowel diseases.


Q: Is Skilax usage restricted for people with kidney or liver problems?

A: Official warnings state that Skilax is contraindicated in patients with severe renal impairment (a serious form of kidney disease). Separately, the tolerability of the drug has been explored in clinical trials involving participants who have mild liver impairment.


Q: Can women use Skilax during pregnancy or while breastfeeding?

A: Official information advises that Skilax should generally not be taken during pregnancy unless the expected health benefit outweighs any potential risk. However, for breastfeeding, the active component is often undetectable in breastmilk, and it can usually be taken without requiring special precautions.


Q: Why might a doctor prescribe Skilax instead of a different medication?

A: For procedural preparation, Skilax (or combination products containing it) is often utilized because it effectively combines the actions of a stimulant laxative and an osmotic laxative. This dual action is described as a highly effective approach for achieving necessary colon cleansing prior to a medical procedure.


Q: Does Skilax have the potential for dependence or withdrawal symptoms?

A: Because it is a stimulant laxative, medical literature and official warnings regarding prolonged use have explored the potential for dependence if used excessively or long-term. In rare cases, chronic, excessive use of stimulant laxatives has been noted to potentially induce a condition called cathartic colon.


Q: Can Skilax cause long-term side effects that appear years later?

A: Long-term use of Skilax, particularly when excessive, is associated with the possibility of developing fluid and electrolyte imbalances. Regulatory warnings also mention that chronic, excessive use may, in rare instances, lead to the development of a condition called cathartic colon.


Q: How does the mechanism of Skilax differ from traditional treatments for the same condition?

A: Unlike some other treatments, Skilax is defined as a pro-drug, meaning it is inactive until it reaches the large intestine where it is chemically transformed by naturally occurring gut bacteria. Once activated, it acts to both stimulate muscle contractions and increase fluid in the bowel.


Q: What should I do if I miss a scheduled dose of Skilax?

A: Official guidelines provide specific directions for managing missed doses, with procedures that can differ depending on the intended use, such as for short-term relief or for procedural bowel cleansing.


Q: Can Skilax be crushed or split if a patient has trouble swallowing?

A: For the powder formulation often used in procedural cleansing, official instructions state that the powder must be mixed with cold water immediately before consumption. Official instructions indicate the unmixed powder formulation is not intended to be taken directly. Specific instructions for tablets should be confirmed in the package insert.


Q: Does Skilax affect blood pressure or heart rate?

A: Yes, official warnings note that changes in heart rhythm, such as a fast or irregular heartbeat (arrhythmia), are a listed risk resulting from severe electrolyte changes caused by the drug. Additionally, a drop in blood pressure upon standing, known as postural hypotension, is a possible adverse event.


Q: Is Skilax expensive, and is a generic version available?

A: While the price itself is not regulated, drug status information confirms that a generic version of the active ingredient is available as a prescription-only medication. Some brand-name versions may have varying availability in the marketplace.


Q: What kind of monitoring or check-ups are generally required while on Skilax?

A: Due to the risk of inducing changes in essential body salts, regulatory documents state that laboratory assessments (such as blood tests) may be considered by healthcare providers before and after use, especially for patients who may have an increased risk of fluid or electrolyte abnormalities.


Q: Can Skilax cause sleep-related issues, such as insomnia or drowsiness?

A: Yes, official documents and clinical studies have reported sleep disturbance as a common adverse event associated with the use of this medication.


Q: Does the efficacy of Skilax change over time with continued use?

A: Its use for non-procedural needs is generally restricted to a short-term duration. Official information states that prolonged excessive use may lead to changes in the desired effect.


Q: Are there any known interactions between Skilax and common cold/flu medications?

A: Official documents warn that the accelerated movement through the gastrointestinal tract may modify the absorption of other orally administered medicines. This is important for cold and flu medications, many of which are taken orally.


Q: What are the official storage conditions described for Skilax?

A: General storage advice found in official product information specifies that the medication should be kept out of the reach of children. It should also be stored appropriately, typically away from light, excessive heat, and moisture.


Q: How is the safety profile of Skilax described in official regulatory documents?

A: The safety profile described in regulatory documents is characterized primarily by the risk of serious complications stemming from fluid and electrolyte abnormalities (imbalances in body salts). These complications can include seizures, irregular heartbeat, and potential kidney issues.


Q: What are the main contraindications listed for Skilax in official labeling?

A: Official labeling lists the main contraindications (reasons the drug must not be used). These include a state of severe dehydration, evidence of a gastrointestinal obstruction or perforation, and a condition of severe renal impairment (kidney disease).


Q: Is the brand name Skilax sold under other names internationally?

A: Official drug information confirms that the active ingredient in Skilax is sold under various different brand names internationally, including names like Laxoberal, Picolax, and Prepopik.


Q: Can Skilax affect mood or cause emotional changes?

A: Official warnings list potential mood changes and confusion as symptoms that may result from severe electrolyte or fluid abnormalities. These effects are noted in the context of ensuring proper body fluid balance during use.


Q: Is it normal to feel pain or cramping when using Skilax?

A: Yes, official regulatory documents list abdominal pain and cramping as common adverse reactions associated with the use of this medication.

How should Skilax be stored and disposed of?

Skilax (sodium picosulfate) products must be stored strictly according to regulatory labeling to maintain integrity.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at room temperature, typically below 25°C or 30°C. Do not refrigerate or freeze the medicine.
Protection Keep the product away from light, heat, and moisture; ensure the bottle is tightly closed [Source: Highnoon Labs].
Stability Any remaining oral solution after use must be discarded and not stored [Source: SODIUM PICOSULFATE ORAL SOLUTION "TOWA"].
Safety Keep the medicine out of the sight and reach of children [Source: Dulcolax Twelve Plus Pico Liquid PIL].

Disposal Requirements

Official disposal instructions advise against throwing away medication via wastewater or household waste [Source: Dulcolax Twelve Plus Pico Liquid PIL]. Unused or expired medication should be disposed of in consultation with a pharmacist, who provides guidance aligned with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Skilax found in:

A-Z Index: